Skip to main content

Table 3 A sensitivity analysis

From: Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials

 

Number of studies

OR

95% CI

P for overall effect

I2 %

Studies with low risk of bias

8

0.25

0.09 to 0.68

0.007

0

Levosimendan versus placebo

9

0.66

0.11 to 4.08

0.65

35

Levosimendan versus phosphodiesterase

4

0.23

0.08 to 0.65

0.003

0

Levosimendan versus dobutamine

4

0.54

0.25 to 1.17

0.12

43

  1. A sensitivity analysis including only studies with a low risk of bias, and comparing levosimendan to placebo, phosphodiesterase inhibitors and dobutamine.
  2. OR, odds ratio; I2, heterogeneity
Back to article page

Critical Care

ISSN: 1364-8535